
Esther Segal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/349115/publications.pdf Version: 2024-02-01



FSTHED SECAL

#	Article	IF	CITATIONS
1	OUP accepted manuscript. Medical Mycology, 2022, , .	0.7	2
2	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infectious Diseases, The, 2021, 21, e375-e386.	9.1	80
3	Human and Zoonotic Dermatophytoses: Epidemiological Aspects. Frontiers in Microbiology, 2021, 12, 713532.	3.5	35
4	Educational Session at the "Trends in Medical Mycology―(TIMM) 2021 Congress Teaching Medical Mycology to Students of Medicine. Journal of Fungi (Basel, Switzerland), 2021, 7, 953.	3.5	0
5	Dermatomycoses in the Israeli defense forces—Epidemiological and clinical aspects. Mycoses, 2020, 63, 65-70.	4.0	4
6	Fungi in sands of Mediterranean Sea beaches of Israel—Potential relevance to human health and wellâ€being. Mycoses, 2020, 63, 1255-1261.	4.0	8
7	European confederation of medical mycology expert consult—An ECMM excellence center initiative. Mycoses, 2020, 63, 566-572.	4.0	8
8	<i>Galleria mellonella</i> as a model system to study virulence potential of mucormycetes and evaluation of antifungal treatment. Medical Mycology, 2019, 57, 351-362.	0.7	54
9	ECMM <i>Candi</i> Reg—A ready to use platform for outbreaks and epidemiological studies. Mycoses, 2019, 62, 920-927.	4.0	19
10	Azole-Resistance in Aspergillus terreus and Related Species: An Emerging Problem or a Rare Phenomenon?. Frontiers in Microbiology, 2018, 9, 516.	3.5	66
11	Experimental In Vivo Models of Candidiasis. Journal of Fungi (Basel, Switzerland), 2018, 4, 21.	3.5	49
12	Diagnostic Aspects of Veterinary and Human Aspergillosis. Frontiers in Microbiology, 2018, 9, 1303.	3.5	31
13	Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together. Mycoses, 2018, 61, 885-894.	4.0	52
14	Phenotypic and genotypic characteristics of <i>Candida albicans</i> isolates from bloodstream and mucosal infections. Mycoses, 2017, 60, 534-545.	4.0	12
15	Testing Antifungal Vaccines in an Animal Model of Invasive Candidiasis and in Human Mucosal Candidiasis. Methods in Molecular Biology, 2017, 1625, 343-353.	0.9	6
16	Beach sand and the potential for infectious disease transmission: observations and recommendations. Journal of the Marine Biological Association of the United Kingdom, 2016, 96, 101-120.	0.8	80
17	Onychomycosis in Israel: epidemiological aspects. Mycoses, 2015, 58, 133-139.	4.0	29
18	Dermatophyte infections in environmental contexts. Research in Microbiology, 2015, 166, 564-569.	2.1	24

ESTHER SEGAL

#	Article	IF	CITATIONS
19	Multilocus sequence typing ofCandida albicansisolates from candidemia and superficial candidiasis in Israel. Medical Mycology, 2013, 51, 755-758.	0.7	13
20	Immunization Protocols for Use in Animal Models of Candidiasis. Methods in Molecular Biology, 2009, 499, 27-34.	0.9	0
21	<i>Candida albicans</i> metabolite affects the cytoskeleton and phagocytic activity of murine macrophages. Medical Mycology, 2008, 46, 251-258.	0.7	14
22	Gene transcription studies ofCandida albicansfollowing infection of HEp2 epithelial cells. Medical Mycology, 2006, 44, 329-334.	0.7	31
23	Infection of HEp2 epithelial cells withCandida albicans: adherence and postadherence events. FEMS Immunology and Medical Microbiology, 2006, 46, 470-475.	2.7	11
24	Candida, still number one - what do we know and where are we going from there?. Candida, immer noch Nummer Eins: Was wissen wir, und wie geht es weiter?. Mycoses, 2005, 48, 3-11.	4.0	64
25	Adherence of Aspergillus species to soft contact lenses and attempts to inhibit the adherence. Mycoses, 2001, 44, 464-471.	4.0	6
26	Experimental candidosis. Pathogenesis, prevention, therapy. Mycoses, 1999, 42, 55-59.	4.0	3
27	Adhesion of <i>Candida albicans</i> to epithelial cells ―effect of nikkomycin. Mycoses, 1997, 40, 33-39.	4.0	6
28	Inhibitors of Candida Albicans Adhesion to Prevent Candidiasis. Advances in Experimental Medicine and Biology, 1996, 408, 197-206.	1.6	8
29	Adhesion of Candida albicans to epithelial cells effect of polyoxin D. Mycopathologia, 1991, 115, 197-205.	3.1	18
30	Fungal ribosomal vaccines. Mycopathologia, 1989, 105, 45-48.	3.1	5
31	Candidal vaginitis in hormone-treated mice: Prevention by a chitin extract. Mycopathologia, 1988, 102, 157-163.	3.1	21
32	Effect of Candida albicans cell wall components on the adhesion of the fungus to human and murine vaginal mucosa. Mycopathologia, 1988, 102, 115-121.	3.1	40
33	Vaccines Against Fungal Infections. CRC Critical Reviews in Microbiology, 1987, 14, 229-271.	4.8	19
34	Correlative relationship between adherence ofCandida albicansto human vaginal epithelial cellsin vitroand candidal vaginitis. Medical Mycology, 1984, 22, 191-200.	0.7	56
35	Cell-mediated immunity following experimental vaccinations with Candida albicans ribosomes. Mycopathologia, 1983, 83, 161-168.	3.1	16
36	Rhodotorula rubra – Cause of Eye Infection. Mycoses, 1975, 18, 107-111.	4.0	7

#	Article	IF	CITATIONS
37	Rhodotorula rubra - Cause of Eye Infection. Mycoses, 1962, 5, 107-111.	4.0	4